Digital signage supplier Mediazest (LON: MDZ) performed strongly in the year to September 2025 and it made a pre-tax profit. Annual revenues are estimated to be 30% higher at £4m. Customers are rolling out digital signage in their outlets. Cash was £100,000. A debt restructuring has led to a £529,000 interest write off, leaving £786,000 owed that will be paid off over six years. The share price jumped 51.7% to 0.11p.
Oil and gas company Kistos (LON: KIST) is acquiring a 5% interest in Block 9 and a 20% interest in Blocks 3 and 4 in onshore Oman from Mitsui E&P Middle East for $148m. This should add 25.6 million barrels of oil equivalent reserves. There will be additional net production of up to 10,000 barrels per day. The deal is immediately cash generative. The share price gained 21.4% to 179p.
Medical imaging company IXICO (LON: IXI) reported 2024-25 figures ahead of expectations. Revenues were 13% ahead at £6.5m and the £1.7m underlying loss was lower than anticipated. Cavendish has reduced the forecast 2025-26 loss to £1.6m. The share price improved 14% to 12.25p.
Dispute resolution service provider Diales (LON: DIAL) continues to improve underlying profit, but there could be more to come if utilisation levels improve. Revenues were flat at £43m, but pre-tax profit improved from £1.2m to £1.4m. Net cash was £3m at the end of September 2025. The dividend is maintained at 1.5p/share. The core UK and European operations, which are the hub of the business, improved their profit as did the other regions, except for Asia Pacific which continues to make a small loss. Group utilisation rates are currently 71.6% and the company believes that this could reach 80%, but that will not happen immediately. A pre-tax profit of £1.5m is forecast for 2025-26 and cash could improve to £3.4m. The share price rose 11.1% to 20p.
FALLERS
Shares in Wishbone Gold (LON: WSBN) continue to decline following yesterday’s statement on the progress of drilling at the Red Setter gold dome project in Australia, which disappointed investor. The company plans to release assay results for over the next few months. It will then formulate a plan for 2026. The share price fell a further 15.7% to 43p and has lost around one-third so far this week.
Chronic kidney disease risk assessment test developer Renalytix (LON: RENX) is focusing on converting business development activity into contracted relationships and growing testing volumes. The kidneyintelX.dkd test is becoming more widely adopted. A deal with Tempus AI Inc is helping to widen the distribution of the test, but there can be lengthy implementation and approval processes. There will be a trading statement in January. The share price slid 7.41% to 6.25p.
Hot summer weather and tougher economic conditions held back XP Factory (LON: XPF), but it still managed to grow, helped by new openings. Escape Hunt did increase like-for-like revenues in the first half after a poor first quarter. However, like-for-like revenues for Boom Battle Bars were 6.8% lower, which is still better than its sector. Overall revenues were 13% higher at £28.2m. There was a first half loss, but £1.4m of free cash was generated. Net debt was £5.3m at the end of September 2025 and there is plenty of finance for further openings. Christmas is the key part of the year, and orders are higher than last year. Like-for-like Escape Hunt revenues are 8.3% ahead so far in the second half, but Boom’s are 9.8% lower. Full year underlying pre-tax profit is expected to rise from £800,000 to £1.1m, but that will depend on Christmas. The share price slipped 6.52% to 10.75p.
Scancell (LON: SCLP) says that the phase 2 SCPE trial with iSCIB1+ for advanced melanoma shows that it is better than the standard of care. Recent meetings with the FDA have been positive and the scope of the phase 3 registrational trial has been confirmed. Cash will last into the second half of 2026. The share price dipped 4.39% to 9.8p.